Why do we need pharma to share this vaccine technology?
Currently, many low- and middle-income countries (LMICs) are almost entirely dependent on imports and donations of COVID and other vaccines, contributing to vaccine inequity.
If Moderna, Pfizer and BioNTech shared their mRNA vaccine technology and know-how with the rest of the world, the production and supply of lifesaving vaccines could be diversified and expanded, for COVID and beyond.
With access to mRNA technology, capable manufacturers in LMICs could produce vaccines for emerging COVID variants, as well as other infectious diseases such as HIV, tuberculosis and malaria. They could also be prepared to swiftly produce vaccines for future pandemics.
The Access Campaign is working with others to push pharma to share the technology and also to encourage manufacturers to step up to receive the technology and training required to start vaccine production.